Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02727660 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)
A Phase 3 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,876
- Enrollment target
NCT02727660 is a Phase 3 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 1,876 participants.
The verdict
NCT02727660, a Phase 3 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,876 participants
- Enrollment target
Study Summary
This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD exacerbation and lung function study with PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all administered BID.
Interventions
- DRUG BFF MDI (PT009) 320/9.6 μg
- DRUG BFF MDI (PT009) 160/9.6 μg
- DRUG FF MDI (PT005) 9.6 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,876 participants |
| Start Date | 2016-04-29 |
| Est. Completion | 2018-04-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02727660
The ClinicalTrials.gov registry entry for NCT02727660 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,876 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BFF MDI (PT009) 320/9.6 μg is the first listed.
NCT02727660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02727660 about?
NCT02727660 is a clinical study titled "A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)". This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD exacerbation and lung function study with PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all administered BID.
What is the current status of trial NCT02727660?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,876 participants. The study started on 2016-04-29. Estimated completion is 2018-04-04.
What interventions are being tested in trial NCT02727660?
The interventions under investigation include: BFF MDI (PT009) 320/9.6 μg (DRUG), BFF MDI (PT009) 160/9.6 μg (DRUG), FF MDI (PT005) 9.6 μg (DRUG).
Who is sponsoring clinical trial NCT02727660?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.